The next generation sequencing (NGS) market is projected to reach $77.2 billion by 2036 from an estimated $21.8 billion in 2026, at a CAGR of 13.5% from 2026 to 2036. The market was valued at $18.9 billion in 2025. The growth of this market is primarily fueled by rising cancer prevalence and the widening clinical application of NGS, and by the declining cost of genome sequencing, which continues to expand the addressable testing volume across both research and clinical settings. Additionally, the expanding application of NGS in personalized medicine and precision oncology, rising adoption of bioinformatics and genomic data management solutions backed by government genomics programs, and supplier consolidation extending reach into single cell, spatial, and proteomic technologies are expected to create substantial growth opportunities for market participants.
The key players operating in the NGS market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Eurofins Scientific SE (Luxembourg), Beijing Genomics Institute (BGI Genomics Co., Ltd.) (China), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), Tecan Group Ltd. (Switzerland), Hamilton Company (U.S.), Hudson (U.S.), LGC Limited (U.K.), Eppendorf AG (Germany), Novogene Co., Ltd. (China), GeneDx Holdings Corp. (U.S.), MGI Tech Co., Ltd. (China), and Quest Diagnostics Incorporated (U.S.).
The NGS market study presents historical market data value (2024), estimated current data (2026), and forecasts for 2036. This market is segmented by offering, application, end user, and geography.
Among all the offerings, the commercial sequencing/outsourced services segment is expected to account for the largest share of the NGS market in 2026 and is also projected to register the fastest growth among the four offering categories. The dominant position of this segment is primarily attributed to the continued preference among institutions that lack in-house instrumentation to route sequencing to contract providers. Sample preparation holds the second-largest share, while data analysis/bioinformatics registers the second-fastest growth rate as the share of workflow spend devoted to interpretation and storage keeps rising.
Among all the applications, the research & other applications segment is expected to account for the larger share of the NGS market in 2026, spanning drug discovery, agriculture & animal research, and other applications. The clinical applications segment is projected to register the higher growth rate of the two, supported by the extension of reimbursement to sequencing-based diagnostic tests and the growth of reproductive health and rare disease testing. Within clinical applications, oncology alone accounts for the largest share of the market.
Among all the end users, the pharmaceutical & biotechnology companies segment is projected to account for the largest share of the NGS market in 2026. Hospitals & diagnostic laboratories is the fastest-growing end-user category and is expected to overtake pharmaceutical & biotechnology companies in absolute value before the end of the forecast period. Academic institutes & research centers register the slowest growth, reflecting constrained public research funding.
Among all the geographies, North America is projected to hold the largest share of the NGS market in 2026. The region's leadership reflects the concentration of sequencing platform manufacturers, an established reimbursement framework linking coverage to companion diagnostic status, and the scale of pharmaceutical research activity. Asia-Pacific is projected to register the fastest CAGR during the forecast period of 2026-2036, supported by the scale of the region's population, expanding molecular diagnostic capability, the growth of domestic manufacturing, and national genomics programs across China, Japan, India, and Singapore.
The key players operating in the NGS market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Eurofins Scientific SE (Luxembourg), Beijing Genomics Institute (BGI Genomics Co., Ltd.) (China), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), Tecan Group Ltd. (Switzerland), Hamilton Company (U.S.), Hudson (U.S.), LGC Limited (U.K.), Eppendorf AG (Germany), Novogene Co., Ltd. (China), GeneDx Holdings Corp. (U.S.), MGI Tech Co., Ltd. (China), and Quest Diagnostics Incorporated (U.S.).
The NGS market study presents historical market data value (2024), estimated current data (2026), and forecasts for 2036. This market is segmented by offering, application, end user, and geography.
Among all the offerings, the commercial sequencing/outsourced services segment is expected to account for the largest share of the NGS market in 2026 and is also projected to register the fastest growth among the four offering categories. The dominant position of this segment is primarily attributed to the continued preference among institutions that lack in-house instrumentation to route sequencing to contract providers. Sample preparation holds the second-largest share, while data analysis/bioinformatics registers the second-fastest growth rate as the share of workflow spend devoted to interpretation and storage keeps rising.
Among all the applications, the research & other applications segment is expected to account for the larger share of the NGS market in 2026, spanning drug discovery, agriculture & animal research, and other applications. The clinical applications segment is projected to register the higher growth rate of the two, supported by the extension of reimbursement to sequencing-based diagnostic tests and the growth of reproductive health and rare disease testing. Within clinical applications, oncology alone accounts for the largest share of the market.
Among all the end users, the pharmaceutical & biotechnology companies segment is projected to account for the largest share of the NGS market in 2026. Hospitals & diagnostic laboratories is the fastest-growing end-user category and is expected to overtake pharmaceutical & biotechnology companies in absolute value before the end of the forecast period. Academic institutes & research centers register the slowest growth, reflecting constrained public research funding.
Among all the geographies, North America is projected to hold the largest share of the NGS market in 2026. The region's leadership reflects the concentration of sequencing platform manufacturers, an established reimbursement framework linking coverage to companion diagnostic status, and the scale of pharmaceutical research activity. Asia-Pacific is projected to register the fastest CAGR during the forecast period of 2026-2036, supported by the scale of the region's population, expanding molecular diagnostic capability, the growth of domestic manufacturing, and national genomics programs across China, Japan, India, and Singapore.
Key Questions Answered in the Report:
- What is the current revenue generated by the NGS market globally?
- At what rate is the NGS market demand projected to grow for the next 10 years?
- What are the historical market sizes and growth rates of the NGS market?
- What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
- Which segments in terms of offering, application, and end user are expected to create major traction for the manufacturers in this market?
- What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the manufacturers operating in the NGS market?
- Who are the major players in the NGS market? What are their specific product offerings in this market?
- What are the recent strategic developments in the NGS market? What are the impacts of these strategic developments on the market?
Table of Contents
1 Introduction
2 Research Methodology
4 Market Insights
5 Market Assessment—By Offering
6 Market Assessment—By Application
7 Market Assessment—By End User
8 Market Assessment—By Geography
9 Competition Analysis
10 Company Profiles
11 Appendix
List Of Tables
List of Figures
Companies Mentioned
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd.
- Eurofins Scientific SE
- Beijing Genomics Institute
- QIAGEN N.V.
- Agilent Technologies, Inc.
- Revvity, Inc.
- Pacific Biosciences of California, Inc.
- Danaher Corporation
- Oxford Nanopore Technologies Plc.
- Tecan Group Ltd.
- Hamilton Company
- Hudson
- LGC Limited
- Eppendorf AG
- Novogene Co., Ltd.
- GeneDx Holdings Corp.
- MGI Tech Co., Ltd.
- Quest Diagnostics Incorporated (U.S.).
